Neuberger Berman Group’s Atea Pharmaceuticals AVIR Stock Holding History

Neuberger Berman Group’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$56.2K	Buy	+12,077	New	+$60.1K	﹤0.01%	2280

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Neuberger Berman Group's AVIR Position: Q2 2026 in Review

Neuberger Berman Group opened a new position in Atea Pharmaceuticals (AVIR) in Q2 2026: 12,077 shares worth $56.2K. The stake represents ﹤0.01% of the portfolio and ranks #2280 among its holdings.

125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

Neuberger Berman Group held 12,077 shares of Atea Pharmaceuticals worth $56.2K as of Q2 2026.
Atea Pharmaceuticals was a new Neuberger Berman Group position in Q2 2026.
Atea Pharmaceuticals made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #2280 holding.
125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.